Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

NEXT STORY
Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations
PREV STORY
Intranasal Drug and Vaccine Market 2028 – Insights on Key Trends, COVID-19 Impact, Value Chain Analysis, Strategic Initiatives, and Future Outlook: Adroit Market Research
Subscribe to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD

First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN ...

author_avatar
NASDAQ Market News

Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer

author_avatar
NASDAQ Market News

Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

author_avatar
NASDAQ Market News